BioCentury, The Bernstein Report on BioBusiness, January 29, 2007, pages 9 and 10
Product Development: COX-2s on the Brain
Article on Affectis by Christopher Maggos, Senior Writer

Download here


Affectis Pharmaceuticals AG In-licenses Clinical Stage Compound for the Treatment of Psychiatric Disorders

January 23, 2007 – News Release
Munich, Germany and Barcelona, Spain – Affectis Pharmaceuticals AG, a biopharmaceutical company developing novel drugs for the treatment of depression and schizophrenia, announced today that it has in-licensed a novel, selective Cox-2 inhibitor from Palau Pharma, the R&D subsidiary of Grupo Uriach. Affectis will develop the compound, named Cimicoxib, as a treatment for depression and schizophrenia. The company expects to start a Phase II trial in depression with Cimicoxib this year.
more...

Download German version


back to latest News 2007